Abstract 530P
Background
Recent evidence have showed that high level of systemic inflammation is associated with poor survival in patients with malignancy by promoting cell proliferation. Inflammation-based serum biomarkers including C Reactive Protein (CRP), Albumin (ALB) and CRP/ALB ratio have been showed to have prognostic value in patients with Small Cell Lung Cancer (SCLC). C-reactive protein (CRP) is a nonspecific serum marker of acute-phase inflammatory response. Studies have hypothesized that High CRP is a surrogate marker of tissue inflammation secondary to tumor growth. Albumin is both an inflammatory and nutritional marker. They are readily available and cost-effective tests that are potential prognostic biomarkers and therapeutic targets. Prognostic biomarkers help to optimize therapy decisions, as they provide information on the likelihood of response to a given chemotherapeutic regimen.
Methods
The databases of PubMed, Cochrane, and Google Scholar were systematically searched until July 2019. Associations between CRP, ALB and CRP/ALB ratio and overall survival (OS) were investigated by pooling hazard ratio (HR) and 95% confidence interval (CI).
Results
A total of 13 studies comprising of 2,034 patients were included. The results showed that only High CRP (HR 1.36, CI 95% 1.01, 1.82 p = 0.04) and High CRP/ALB (HR 1.38, CI 9%% 1.15, 1.64 p = 0.0004) ratio are significantly associated with overall survival. Albumin has no statistical association with OS.
Conclusions
High CRP and CRP/ALB ratio are independent prognostic biomarkers in patients with SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract